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Abstract
Although transfusion of blood components is becoming increasingly safe, the risk of trans-
mission of known and unknown pathogens persists. The application of vitamin B2 (ribo-
flavin) and UV light to pathogen inactivation has several appealing factors. Riboflavin is 
a naturally occurring vitamin with a well-known and well-characterized safety profile. 
This photochemical-based method is effective against clinically relevant pathogens and 
inactivates leukocytes without significantly compromising the content and the efficacy 
of whole blood or blood component. This chapter gives an overview of the innovative 
technology for pathogen inactivation, the Mirasol® pathogen reduction technology (PRT) 
System, based on riboflavin and UV light, summarizing the mechanism of action, toxicol-
ogy profile, pathogen reduction performance and clinical efficacy of the process.
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1. Introduction
The collection, processing, transfusion of whole blood, red blood cells, platelets, plasma, and 
infusion of fractionated plasma components are essential medical practices, often required 
for the preservation of life and for the treatment of disease. Although the transfusion/infusion 
of these components is a vital therapy, transfusions are still associated with some risk for 
transmission of disease to the patient [1].
Worldwide measures to reduce the risk of transmission of diseases to recipients through 
blood have been continuously implemented and improved [2]. Blood safety improvements 
include donor’s questionnaire, self-deferrals and donation screening methods designed to 
detect possible contaminating agents in blood. Serological testing and nucleic acid testing 
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have become staples of modern blood banking and have greatly reduced the risk of disease 
transmission by blood product transfusion. Yet, growing socio-political changes of contempo-
rary society together with environmental changes challenge the practice of blood transfusion 
with a continuous source of unforeseeable threats with the emergence and re-emergence of 
blood-borne pathogens [2, 3].
In the last two decades, several pathogen reduction/inactivation technologies (PRT) have 
been developed to allow treatment of blood products with the intent of reducing the levels of 
infectivity and eventually inactivating white blood cells that can cause immunological com-
plications to blood recipients. PRT methods involve physicochemical disruption of patho-
gen structural elements, mostly applied to the production of plasma-derived fractionated 
products or photochemical modification of nucleic acids to prevent replication, applicable to 
labile blood components like platelet concentrates, therapeutic plasma and eventually red cell 
concentrates [4, 5].
One of these PRT technologies, the Mirasol PRT System, uses riboflavin or vitamin B2 as 
a photochemical sensitizer and relies on the association of riboflavin with nucleic acid and 
activation with UV-light to generate a photochemical reaction that modifies guanine residues 
and thus prevents replication processes. This method creates irreversible damage via electron 
transfer processes at the sites where riboflavin-guanine base chemistry occurs [6].
Flavins are present in all biologic fluids and tissues. The most common biologically important 
flavins are riboflavin and its nucleotides: riboflavin-5′-phosphate (flavin mono-nucleotide, 
FMN), and the intramolecular complex of FMN with adenosine-5′-monophosphate (flavin 
adenine dinucleotide, FAD) [7]. Riboflavin in its coenzyme form is a component of many 
oxidation-reduction reactions and of energy production. It is essential for growth and tissue 
repair in all animals from protozoa to man [8] unlike fat-soluble vitamins, which are stored 
in body fat, riboflavin is a water-soluble vitamin and excess amounts are rapidly excreted. 
Because there are no physiological stores of riboflavin and excretion is constant, frequent 
dietary intake is important to maintain sufficient concentration and in the case of excess, 
return to normal levels is commensurate with renal function [9].
The choice of riboflavin as photosensitizer in the Mirasol PRT System was reinforced by its 
well-documented safety profile, being widely used as food coloring in the United States, 
where it is “generally regarded as safe” by the FDA [10]. Neonates, including preterm and 
very low birth weight (VLBW) infants, requiring nutritional supplementation due to imma-
ture gastrointestinal and metabolic systems, commonly undergo parenteral nutrition with a 
multivitamin preparation which includes vitamin B12, thiamine, folate and riboflavin [11]. 
The FDA concluded in their review that the LD
50
 is orders of magnitude greater than the 
Recommended Daily Allowance (RDA); additionally, no reports on carcinogenicity, muta-
genicity or teratogenicity associated with riboflavin have been reported to the agency [12]. 
In Europe, it has been approved by the Scientific Committee on Food [13]. Furthermore, an 
anti-neoplastic action of riboflavin photoproducts to hematological malignancies and solid 
tumors has been postulated, whereas high dose of riboflavin has been suggested for migraine 
prophylaxis [14–16].
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2. Vitamin B2 and UV light: the chemistry
Riboflavin (RB) has absorption maxima at 220, 265, 375, and 446 nm in water and is yellow-
orange in color. When aqueous solutions containing RB are exposed to sunlight, RB is con-
verted into lumichrome (LC) under neutral conditions, and into lumiflavin (LF) in alkaline 
solutions [17, 18]. LC is also a known metabolic breakdown product of RB in the human 
body [19]. Flavin systems are known to be photochemically active, and the products of flavin 
photochemistry are known [17, 19, 20].
The mechanism of pathogen reduction using RB likely involves three potential pathways: 
Type I Photochemistry [47, 48] Type II Photochemistry, [21] and the effects of UV light alone. 
The contribution of each of these three pathways to the Mirasol PRT System pathogen reduc-
tion process has been described in the literature.
The reported mode of action of RB in the reduction of pathogens is postulated to be based in 
part on the ability of RB to interact with nucleic acids and to undergo chemistry with those 
nucleic acids upon exposure to light. This chemistry is believed to involve both oxygen-depen-
dent and oxygen-independent (electron transfer) processes. It has been described thoroughly 
in the chemical literature over the past several decades [22–30]. The use of UV light with plate-
lets and plasma also affords a third contributor to pathogen kill via the direct action of light.
2.1. Action spectra and absorbance spectra
Figure 1 depicts the action spectrum of RB and lambda phage minus light alone (yellow) 
over-laid with the absorbance profile of RB in PBS (pink) and absorbance of DNA in PBS 
(blue). At wavelengths lower than 300 nm, RB acts to shield the effects on DNA due to the 
Figure 1. Action spectra and absorbance spectra of riboflavin with lambda phage.
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direct action of UV light. Greater levels of inactivation in the presence of RB occur at wave-
lengths between 300 and 350 nm compared to the prediction due to the absorbance profile of 
free RB in solution. This is also observed for wavelengths higher than 500 nm. In the region 
of 308–575 nm, in order to achieve the same magnitude of log reduction that was observed 
between 266 and 304 nm, the energy required for the experiments between 308 and 575 nm 
was increased 50-fold from 0.1 to 5.0 J/mL. There is no inactivation of lambda phage with light 
of wavelength ≥330 nm in the absence of RB.
The action spectrum (AS) do not correlate perfectly with the absorption curve of either RB 
or LC in PBS over the entire wavelength regime. There appears to be essentially an identical 
amount of viral inactivation at 355 and 500 nm, although the optical densities (of solutions 
containing the same concentration of RB) differ by a factor of five at these two wavelengths. 
The phage reduction obtained at 320 nm and at 500 nm is greater than that expected based 
on the absorption spectrum of RB in PBS at these wavelengths. The effect is clearly seen in 
Figure 1 which plots lambda phage inactivation achieved in the presence of RB at various 
concentrations minus that realized in its absence.
2.2. RB sensitized modification of nucleic acids
Several studies have been conducted in order to examine the ability of RB sensitization to 
modify nucleic acids [31]. The DNA fragmentation studies in leukocytes and bacteria utilized 
chemical agents that bind to portions of the DNA strand, which have been severed or broken 
because of chemical modification. The fragments that are produced leave regions that can 
be chemically tagged with a fluorescence probe and subsequently measured to provide an 
estimate of the extent of fragmentation that has occurred. Single-strand breaks throughout 
the nucleic acid sequence can be identified in this way. More complete breaks leading to 
denaturation of the nucleic acid can also be monitored by gel electrophoresis. In the latter 
case, the complete denaturation of the nucleic acid can be followed by examining migration 
patterns on polyacrylamide gels [31, 32]. This assay looks for much more severe and complete 
nucleic acid degradation than single-strand breaks.
In one set of studies, the level of DNA fragmentation occurring in white cell DNA was deter-
mined using a flow cytometric assay (Trevigen Apoptotic Cell System (TACS) assay. The level 
of DNA fragmentation obtained was significantly increased in the presence of RB. Similar 
observations were made for samples of plasmid DNA and for DNA isolated from Escherichia 
coli following treatment in the presence and absence of RB [31]. These combined studies dem-
onstrate a sensitizing effect, with respect to nucleic acid damage, which RB imparts to samples 
treated with UV light. These observations are consistent with literature reports for RB.
Cadet and co-workers have evaluated the chemistry involved in the formation of specific 
lesions induced in nucleic acids by RB and light. These lesions differ from those induced by 
exposure to light alone in that chemically distinct oxidized species of guanine where residues 
are formed. This chemistry DNA fragmentation in isolated white cell DNA following expo-
sure to light in the presence and absence of RB was evaluated because of the fact that mamma-
lian systems do not normally contain enzymatic systems capable of repairing these types of 
lesions. This is in stark contrast to the predominant lesion (thymine-thymine dimers formed) 
upon exposure of nucleic acids or agents containing nucleic acids to light alone [33–35].
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These studies identify the precise site of the lesions induced in nucleic acids treated with 
monochromatic 266, 308, or 355 nm light from either an excimer or Yttrium Aluminum Garnet 
(YAG) laser in the presence and absence of RB. The results demonstrate that in the presence of 
RB, the predominant modifications occur to guanine bases, as evidenced by the formation of 
8-oxodGuo. The extent of the oxidized guanines formed in the presence of RB is far in excess 
of those observed upon exposure to light alone. These results are consistent with the literature 
reports of Cadet and co-workers of the mechanism of action of RB with regard to nucleic acid 
chemistry [24]. The results were contrasted to those using UV light alone in the absence of RB, 
and suggest that the addition of RB to the system specifically enhances the damage to DNA 
induced by UV light alone.
2.3. Phage reactivation
Virus reactivation is a phenomenon, which is known to occur through the use of host cell 
nucleic acid repair mechanisms. In the context of virus inactivation, the desired end target 
for these treatments is the prevention of virus replication. It is also desirable, in this context, 
to prevent repair of damaged virus particles because such repairs may render non-infectious 
agents capable of transmitting the disease when re-infused. This may be accomplished by 
generating either an extent of damage that the host system cannot repair or a type of damage 
that the host system does not have the capability of repairing.
Studies of the inability of bacteriophage to repair the lesions (Weigle reactivation) induced by RB 
and light as contrasted to the observations with light exposure alone have been conducted [31]. 
These studies confirm that the rescue of DNA damaged phage does not occur to the same extent 
when RB is present in samples exposed to light. These observations are consistent with the data 
suggesting that the presence of RB and UV light selectively enhances damage to the guanine 
bases in DNA or RNA. These data also suggest that this type and extent of damage to nucleic 
acids of virus in the presence of RB makes it less likely to be repaired by normal repair pathways 
available in host cells [36]. This result is essential for a system intended to assure the highest and 
most complete levels of pathogen inactivation attainable.
In summary, the Mirasol PRT process works through three independent mechanisms of 
action in rendering pathogens inactive. These include oxygen dependent chemistry induced 
by the combination of RB and light, electron transfer chemistry induced by the direct interac-
tion of excited RB molecules with nucleic acid base pairs (primarily guanine bases) leading 
to oxidation products, and effects that are due to the action of UV light alone. In essence, the 
presence of RB in this system enhances the effects, which are due to UV light alone, creating a 
condition of greater sensitivity of the pathogen to the UV light to which the sample is exposed 
(photosensitization effect). The combination of these three modes affords broad and extended 
levels of pathogen inactivation with this process.
3. Toxicology and safety
Although the safety of RB has been extensively studied, there were no reports that directly 
supported its use in the Mirasol PRT System. Therefore a comprehensive preclinical safety 
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evaluation program in support of the Mirasol PRT System, designed to investigate all poten-
tial sources of concern, was conducted as part of the overall development program. In vivo 
animal and in vitro toxicity studies were performed using RB, lumichrome and photolyzed 
RB (see Table 1).
To obtain a consistent test article in as humane a fashion as possible for those studies, species-
specific plasma was used rather than platelets. The photochemistry of RB yields equivalent pho-
toproduct profiles in plasma products and in platelet products (which consist mainly of plasma). 
The absence of platelets eliminates the possibility of detecting toxic alterations to the platelet 
surface; however, that issue was addressed in the neoantigenicity and 14C-RB binding studies.
3.1. Systemic toxicity
No toxicologically significant findings were observed in any of the studies of acute toxicity. In 
the repeated-dose toxicity study, the levels of RB and lumichrome in blood samples from ani-
mals receiving Mirasol PRT-treated products were below the limits of quantification, as were the 
levels in blood samples from animals receiving untreated plasma. These results were consistent 
with the observed rapid clearance of RB after IV administration, both in the literature [9] and in 
the pharmacokinetic study with 14C-RB in Mirasol PRT-treated products. RB and its photoprod-
ucts naturally occur in human blood, see Figure 2. All photoproducts were found to be present 
in apheresis platelet products that had not undergone any photochemical treatment, although 
at a much lower concentration. The presence of these agents in human blood, the ubiquitous 
nature of RB exposure, its presence in human diets and the ability of humans to metabolize it 
and manage its inherent photochemistry suggests a low risk profile for this product.
3.2. Developmental toxicity and genotoxicity
No developmental toxicity was observed in the embryo-fetal development study. All fetuses 
were examined for malformations and developmental variations. No mutagenicity was 
• Acute Toxicity* Negative
• Neoantigenicity* Negative
• Ames Mutagenicity# Negative
• CHO Clastogenicity# Negative
• Cytotoxicity# Negative
• Reproductive Toxicity* Negative
• Subchronic Toxicity* Negative
• MMN Genotoxicity* Negative
• Blood Compatibility# Passed
• Leachables and Extractables# Passed
Table 1. In vivo* and in vitro# toxicology.
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observed in the Ames test for treated or control human platelets, or for lumichrome. The 
in vitro and in vivo tests for clastogenicity in mammalian cells (chromosomal aberration in 
cultured CHO cells and micronucleus test in mouse bone marrow cells, respectively) were 
also performed with Mirasol PRT-treated products. Human platelets treated with the Mirasol 
PRT System gave negative results in all genotoxicity experiments.
3.3. Neoantigenicity and cytotoxicity
Results of studies using 14C-labeled RB and exposure of platelets and plasma to UV light 
did not demonstrate any detectable binding of RB or its photoproducts to platelets or to 
plasma proteins. No evidence of neoantigenicity was observed with the Ouchterlony assay, 
indicating that no new antigens were formed during treatment with the Mirasol PRT System. 
Treatment with the Mirasol PRT System did not result in greater immunoglobulin G bind-
ing than what was observed in comparison with untreated controls, when assessed with the 
Capture-P assay. In the tests of lumichrome cytotoxicity, and of the cytotoxicity of Mirasol 
PRT-treated products, no cytotoxicity was observed.
3.4. Hemocompatibility
In tests of hemocompatibility, no hemolysis was observed. In functional assessments, when 
mixed with thrombocytopenic whole blood, the function of Mirasol PRT-treated platelets was 
well preserved, in comparison with controls [37]. Treated platelets displayed no evidence of 
hyperactivation or hypercoagulability.
3.5. Pharmacokinetics of photolyzed 14C-RB in rats
After a single IV administration of Mirasol treated plasma containing photolyzed 14C-RB, the 
radioactivity was well distributed from the whole blood to tissues selected for assay within 
Figure 2. Riboflavin and its photoproducts are naturally present in human blood; no new compounds are formed after 
Mirasol treatment.
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the first hour postdose. Most of the excreted urinary radioactivity was recovered by 12 h 
postdose, and more than half of all radioactivity was excreted in urine. Blood levels of radio-
activity declined rapidly post-dose, as expected from studies of RB metabolism and excretion 
in humans [9]. Measurements of the radioactivity associated with the 14C-RB-treated plasma 
indicated rapid initial apparent distribution (and/or clearance) from the systemic circulation 
that appeared to be complete within the first 8 to 48 h postdose.
3.6. Leachables and extractables
The leachables and extractables analyses detected no polymeric material in either test or con-
trol platelet products. The Mirasol illumination/storage bag does not contain the plasticizer 
di (2-ethylhexyl)phthalate (DEHP), and testing verified that this plasticizer was not present in 
treated and stored products. No toxicologically relevant concentrations of metals were found. 
These results correlate with those from the biocompatibility testing of the Mirasol illumina-
tion/storage bag elements—all elements were biocompatible.
4. Safety of blood
Blood transfusion safety is considered by the World Health Organization an integral part 
of each country’s national health care policy and infrastructure [38]. In the last four decades 
safety of blood has been positively impacted by technological, economic and social improve-
ments [2]. Improvements in blood processing and storage as per good manufacturing 
practices (GMP), introduction of policies discouraging paid blood donation and successive 
addition of screening tests for known transmissible pathogens, as Hepatitis B virus (HBV), 
Human Immunodeficiency viruses 1 and 2 (HIV-1/2) and Hepatitis C virus (HCV) are among 
the most successful measures to increase quality and safety of blood transfusion worldwide 
[39, 40]. From the late nineties onwards, introduction of nucleic acid testing (NAT) was able 
to minimize the window period of detection of these three viruses in asymptomatic blood 
donors to single days [41, 42].
Yet, in the last 20 years attention has been drawn to blood safety threats by recently known 
and/or re-emergent pathogens such as, Severe Acute Respiratory Syndrome virus (SARS), 
West-Nile Fever virus (WNV), Chikungunya virus (CHIKV), Dengue virus (DENV) or most 
recently ZIKA virus (ZIKV). Epidemics of these diseases are geographical or seasonal in 
nature and may not necessarily require universal reactive measures [2, 43, 44].
These unpredictable threats, as well as the long-recognized risk of bacterial transmission 
through platelet transfusion, may be effectively countered through the novel proactive 
approach with broad applicability and effectiveness, the pathogen inactivation/reduction 
technology (PRT) [4]. PRT has first been used to treat plasma and focused on destroying the 
structural elements of potential pathogens by the solvent-detergent method [45]. By the mid-
nineties, the nucleic acid binding properties of Methylene Blue (MB) became exploited in a 
pathogen inactivation system for fresh frozen plasma using visible light [46].
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Though quite effective for the treatment of plasma, neither of these methods could be used 
for cellular blood products. Two newer technologies have been developed, both using UV 
light and two distinct chemical compounds to enable irreversible breakage of nucleic acids 
and blocking further replication of cells and pathogens. One technology uses amotosalen 
hydrochloric acid or S-59 as the photoactive-compound, which together with its photoprod-
ucts need to be removed from the blood component post-illumination due to its high toxic 
profile [47]. The second system uses riboflavin, a natural vitamin (vitamin B2) of which both 
photoproducts and catabolites are found endogenously in the normal blood and therefore do 
not need to be eliminated from the blood component before transfusion [6, 48, 49].
5. The Mirasol PRT process
Pathogen reduction is a proactive strategy to mitigate the risk of transfusion-transmitted infec-
tions. The Mirasol PRT System consists of an illumination/storage bag, RB solution, and an 
Illuminator that delivers UV light to cause permanent damage to nucleic acids of pathogens 
and leukocytes (see Figure 3). The system has been shown to be effective against clinically 
relevant pathogens [50, 51] and inactivates leukocytes [52] without significantly compro-
mising the efficacy of the product [53–55] or resulting in product loss. The process involves 
transferring the blood component to the Illumination/Storage bag and adding 35 ± 5 mL of 
RB solution (500 μM). The product is then placed into the Mirasol Illuminator and exposed to 
UV light. After illumination, the final PRT treated product can be transfused immediately or 
stored without the need for additional filtration or processing. Treated plasma products are 
transferred to a storage bag appropriate for freezing. The Mirasol PRT System has been devel-
oped with the flexibility of treating plasma and platelet components, as well as whole blood.
Figure 3. Mirasol PRT System.
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5.1. Platelets and plasma
PRT-treated plasma products have been on the market in Europe for more than a decade and 
were issued a CE Mark in 2007 and 2008 for platelets and plasma respectively. FFP intended 
for transfusion to patients with multiple coagulation factor deficiencies (e.g. massive transfu-
sion), emergency reversal of warfarin as well as for therapeutic plasma exchange must contain 
adequate functional levels of coagulation factors and other therapeutically valuable proteins. 
Protein levels should be as close as possible to those found in fresh plasma. Blood component 
processing can affect the quality of plasma products, particularly labile coagulation factors 
such as factors V and VIII.
Mirasol-treated FFP shows high overall protein retention under a broad range of blood bank-
ing conditions. Mirasol-treated FFP meets the European guidelines [56], showing on average 
factor VIIIc levels of 0.8 ± 0.2 IU/ml post treatment. Protein content meets guidelines even 
when whole blood is held overnight at room temperature and plasma is separated up to 18 h 
or frozen up to 24 h after collection. Additionally, anticoagulant factors such as protein C and 
protein S are well preserved after treatment with a 96% retention reported post treatment for 
both proteins. Extended storage of treated plasma at −30°C for up to 2 years does not signifi-
cantly decrease protein quality [57].
Platelet products derived from apheresis or whole-blood can be treated with the system and 
products can be stored either in plasma or platelet additive solutions (PAS) for up to 7 days 
under standard blood banking conditions. It is critical that Mirasol-treated platelets remain 
viable and hemostatically effective. A series of in vitro studies have been performed to assess 
platelet quality after Mirasol treatment, and a correlation between in vitro parameters and 
in vivo performance was established [58]. In these studies pH and lactate production rate were 
found to be most strongly correlated with the in vivo recovery and survival of Mirasol-treated 
platelets. Glucose consumption rate and swirl also showed some correlation with these in vivo 
parameters, though to a lesser extent. P-selectin, pO
2
 and pCO
2
 expression in Mirasol-treated 
platelets, however, were poorly correlated with in vivo platelet recovery and survival. Changes 
in cell quality parameters do occur, cellular metabolism is up-regulated in treated platelets, 
and treatment induces some degree of platelet activation. However, shear-induced adhesion 
is maintained in Mirasol-treated platelets, and mitochondrial function is preserved [37, 59].
5.2. Whole blood: military and developing world
The Mirasol system was further developed for the treatment of whole blood, providing a single 
pathogen reduction and leukocyte inactivation step, followed by the use of the product as whole 
blood or pRBCs. The treatment of RBCs or whole blood has been more challenging due to the 
absorption of light by hemoglobin. Although the peak absorption of hemoglobin (400–450 nm) 
is outside the spectral region of the Mirasol lamp output, the UV light energy dose delivered 
to units of whole blood is normalized for RBC volume (J/mlRBC). In vitro cell quality studies have verified that adequate quality and functionality of the RBCs and plasma components post 
treatment and throughout 21 days of storage is preserved [49]. In addition, crossmatch compat-
ibility of the products is preserved. PRT treatment of whole blood has received CE marking in 
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2015 and is a significant step forward ensuring blood safety where whole blood transfusions 
are routine, such as sub-Saharan Africa and in far-forward combat situations.
6. Pathogen reduction performance
The Mirasol PRT System pathogen reduction process has been evaluated for performance 
against several pathogens. Table 2 summarizes the pathogen reduction results. The data show 
reduction factors ranging from 2 to 6 log (99.0–99.9999% reduction) for each pathogen tested 
with the Mirasol PRT System. Log reduction values reported in the table were calculated by 
determining the number of virus particles present in infectious form prior to treatment and 
the number of virus particles present after treatment. The level of log reduction is reported as 
the starting titer expressed in units of 10× per mL minus the level after treatment expressed 
as the titer in 10× per mL. Because volume was constant in the samples before and after treat-
ment, the unit of volume cancels, resulting in a reported value of log reduction.
For example, a sample containing 1,000,000 infectious virus particles per mL would of course 
have 106 virus particles per mL. If after treatment, only 100 particles per mL were measured in 
tissue culture infectivity assays, this would correspond to 102 virus particles per mL. The log 
reduction reported for this system would be 104 or 4 logs. This corresponds to a reduction in virus 
level of 99.99%. Because values are reported in log units, 100% reduction is never achievable.
Despite the fact that bacterial contamination of blood products poses one of the greatest risks 
for transfusion, there are currently no standards in place that establish a panel of species to 
test or a method to evaluate technology for pathogen reduction. A panel based on published 
hemovigilance studies incorporating those species responsible for the majority of morbidity 
and mortality in transfusion-associated reactions was utilized to guide study targets. Two 
complementary test methods were developed, as described below, to measure bacterial 
reduction performance.
To assess bacterial reduction efficiency of the system, two complementary test methods, known 
as “High Spike Bacterial Titer” and “Low Spike Bacterial Titer” tests, for bacterial reduction 
have been developed to measure the Mirasol PRT System performance. Both methods involve 
inoculation of known titers of bacteria (a “spiking” study) into platelet products followed by 
PRT treatment and subsequent measurement of the presence of bacteria. The objective of the 
High Spike Bacterial Titer experiments is to determine the overall bacterial reduction ability of 
the system against a severely contaminated platelet product. These studies may not, however, 
Pathogen type Typical performance
Viruses (enveloped, non-enveloped; intracellular, extracellular) ~2 to 6 log (99.0–99.9999%)
Parasites (Malaria, Chagas, Babesiosis, Leishmaniasis, Scub typhus) ≥ 3.0 to ≥ 5.0 (≥ 99.9% to ≥ 99.999%)
Bacteria (Gram +, Gram −) ~2 to 5 log (99.0–99.999%)
Table 2. Pathogen reduction performance.
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represent a clinically relevant finding in that viable bacteria remaining after treatment may 
grow to high titers through the storage period. The objective of the “Low Spike Bacterial Titer 
Experiments” is to spike a platelet product with a more clinically relevant bacterial titer, treat the 
product using the Mirasol PRT System, and evaluate the platelet product using a standard cul-
ture system through a 7-day storage period to determine if it has remained culture negative, indi-
cating that the platelet product meets release criteria for transfusion. The system demonstrated 
98% effectiveness in these studies against a broad range of bacteria [60]. The combined data from 
these studies demonstrates the bacterial reduction capability of the system under conditions that 
are still substantially higher challenges than may be anticipated in an actual clinical setting.
7. Clinical performance
There have been 11 completed clinical studies with the Mirasol PRT System for Platelets stored 
in 100% plasma or platelet additive solution (PAS). There are two ongoing clinical studies in 
the United States, one study with platelets and one with RBCs derived from Mirasol-Treated 
Whole Blood. Primary outcome measure in most clinical studies has been levels of circulating 
platelets in thrombocytopenic patient’s blood after prophylactic transfusion. Both CI (count 
increment) and CCI (corrected count increment) are accepted as surrogate markers of platelet 
transfusion efficacy, but they do not necessarily account for platelet function or bleeding out-
comes in patients and they rely upon the assumption that a sufficient number of circulating, 
intact platelets will provide protection against bleeding. Patient factors and platelet product 
variability have been shown in published studies to affect increments, limiting the sensitivity 
of the CCI as a clinical efficacy measure. The CCI at one and 24 h after transfusion is decreased 
in patients receiving PRT treated products, compared to patients receiving control products. 
In two recent clinical trials Grade 2 or higher bleeding was the primary endpoint [55, 66]. 
Although lower CCIs were observed in these 2 studies, no difference in clinically meaningful 
bleeding in thrombocytopenic patients was observed.
The clinical evaluation of the Mirasol Whole Blood system includes a clinical trial in patients 
assessing the incidence of transfusion transmitted Plasmodium spp. infection that was con-
ducted in Kumasi, Ghana [61]. Treatment of whole blood reduced significantly the incidence 
of transfusion-transmitted malaria. The safety profile and clinical outcomes were similar 
between test and control groups.
8. Current adoption for routine use
Since 2007, when the Canadian Consensus Conference on Pathogen Inactivation (PI) con-
cluded that a proactive approach in accordance to the precautionary principle would reduce 
the theoretical risk and help sustain public confidence in the blood supply, many national and 
international committees, such as the Advisory Committee on Blood Safety and Availability 
(ACBSA), USA and the European Committee on Blood Transfusion of the Council of Europe 
discussed the accumulating evidence about the efficacy and safety of PRT [62, 63].
B Group Vitamins - Current Uses and Perspectives138
PRT treatment of blood components is regarded as the next step to increase blood safety 
and support the credibility of blood institutions and health policy makers. However, there 
is a lack of consistency in the decision-making criteria used by regulatory bodies and blood 
operators regarding PRT implementation. The European Directorate for the Quality of 
Medicines & Healthcare of the Council of Europe in its Guide to the Preparation, Use and 
Quality Assurance of Blood Components, 19th Edition defines properties and requirements 
for therapeutic plasma, platelet concentrates and cryoprecipitate treated with PRT [56], yet 
PRT treatment of blood components is mandated in very few countries in Europe. Belgium, 
Switzerland and France have made the use of pathogen-inactivation mandatory for the treat-
ment of platelet concentrates. Plasma treated by PRT is mandatory in Belgium, whereas the 
use of solvent/detergent treated plasma is more widespread in Europe but not mandated by 
national agencies.
The Mirasol PRT system has been gradually adopted in Europe, Asia and Latin-America. A 
hemovigilance program, based on the collection of passive hemovigilance data of Mirasol-
treated components in multiple blood transfusion centers in Europe started in 2010. By 2015 data 
about 94,509 transfused platelet concentrates and 96,115 plasma transfusions were recorded in 
the program [64]. By 2017 over 750,000 disposable treatment sets have been distributed world-
wide and 225,000 transfusion data have been recorded in the hemovigilance program.
9. Future
It is reasonable to envisage a future when all labile blood components will be PR treated 
to ensure a safe and sustainable blood supply in accordance with regional transfusion best 
practices. PR treatment of WB represents the most efficient implementation path to achieve 
this goal. It has been recently demonstrated through a clinical trial in a malaria-endemic 
country that a WB PR technology based upon riboflavin and UV light does reduce the risk 
of transfusion-transmitted malaria [61]. RBCs derived from PR-treated WB have shown 
good quality and recovery in health subjects and are currently being evaluated in a pivotal 
clinical trial [65].
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